A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
Public ClinicalTrials.gov record NCT05556265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
Study identification
- NCT ID
- NCT05556265
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2022 (Actual)
- Primary completion
- Jan 6, 2024 (Actual)
- Completion
- May 16, 2024 (Actual)
- Last update posted
- May 31, 2025
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0016 | Santa Monica | California | 90404-2120 | — |
| Local Institution - 0036 | New Haven | Connecticut | 06510 | — |
| Local Institution - 0018 | Tampa | Florida | 33624-2038 | — |
| Local Institution - 0023 | Clinton Township | Michigan | 48038-1137 | — |
| Local Institution - 0024 | New York | New York | 10029-6501 | — |
| Local Institution - 0019 | Chapel Hill | North Carolina | 27516-4061 | — |
| Local Institution - 0011 | Portland | Oregon | 97201-5134 | — |
| Local Institution - 0032 | Pittsburgh | Pennsylvania | 15213-3403 | — |
| Local Institution - 0012 | Austin | Texas | 78759 | — |
| Local Institution - 0013 | Houston | Texas | 77004-8098 | — |
| Local Institution - 0014 | San Antonio | Texas | 78213-2250 | — |
| Local Institution - 0017 | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05556265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2025 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05556265 live on ClinicalTrials.gov.